
‘Punjab high-burden state for hepatitis C, possibly due to intravenous drug abuse'
July 28 is being marked as World Hepatitis Day in a bid to call for action to end this entirely preventable disease.
Hepatitis A and E are spread through contaminated food and water and infection with these viruses causes acute onset jaundice, which is usually self-limiting but can sometimes progress to acute liver failure, which is potentially life-threatening. On the other hand, hepatitis B and C viruses (HBV and HBC) are spread through infected blood or body fluid exposure, including unsafe sexual and injection practices. They usually cause chronic long-term infections. Hepatitis B and C are silent killers that damage the liver over many years, leading to serious conditions like cirrhosis (scarring of the liver), end-stage liver disease, and even cancer.
At the outpatient liver clinic at the PGIMER, around 800-1,000 patients with chronic viral hepatitis (HBV and HCV) are seen each year, Ajay Duseja, head, Department of Hepatology. PGIMER, said. The expert added that Punjab is a high burden state for hepatitis C, possibly due to intravenous drug abuse.
Punjab has been at the forefront of the fight against hepatitis C, and its approach of decentralising diagnosis and treatment using a hub and spoke ECHO model has been replicated not only nationally but has garnered much international attention, Dr Sunil Taneja, additional professor, PGIMER, said.
A new observation over the last few years is the increase in numbers and severity of hepatitis A virus infection. Almost half of the acute liver failure patients admitted to the Liver ICU in the last 2 years have been due to Hepatitis A, which is a cause for concern, Dr Madhumita Premkumar, additional professor, Department of Hepatology, PGIMER, said.
Hepatitis A has also been presenting atypically, particularly with prolonged jaundice and itching, which may require steroids and even plasma exchange, Dr Nipun Verma, additional professor, Department of Hepatology, PGIMER, said.
Dr Arka De, associate professor, PGIMER, said viral hepatitis is largely preventable, with hepatitis A and B vaccines safe and effective, and newborns should receive the hepatitis B vaccine within 24 hours of birth to prevent transmission from mother to child.
Safety First
Wash your hands after using the restroom and before preparing food. Hepatitis A and E are often spread through contaminated water and food. Ensure that food is properly cooked. Drinking water should be filtered or adequately boiled. Eatables should be kept covered and away from flies.
Avoid intravenous drug abuse, use sterile needles and do not share them. Safe piercings and tattoos are vital, ensure new, sterilised needles, razors and equipment during tattoos, shaving and piercings.
Practice safe sex
The crucial need for testing — Dr Arka stressed that testing is the only way to know if you are infected since chronic hepatitis often has no early symptoms in the initial stages. Early diagnosis is key because it allows for timely treatment, which can prevent severe liver damage and save lives. If you have a history of blood transfusions, injecting drug use, or a family history of hepatitis, or if you are pregnant, it is highly recommended to get tested, according to the expert.
The National Viral Hepatitis Control Program (NVHCP), offers free services for diagnosis and treatment of viral hepatitis patients informed Dr Naveen Bhagat, assistant professor, PGIMER. He added that in Chandigarh and Punjab, free testing and treatment for hepatitis B and C are available at government health facilities, including the PGIMER, and excellent cure rates have been seen with these treatments.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


India Today
4 hours ago
- India Today
How to put an end to Hepatitis B
(NOTE: This article was originally published in the India Today issue dated August 4, 2025)Every 30 seconds, globally, someone dies from hepatitis-related liver infections—amounting to 1.3 million deaths annually as per WHO 2024 estimates. The Hepatitis B Virus (HBV) alone contributes to nearly 900,000 of these deaths, mostly due to cirrhosis and liver cancer. That's more than malaria, and approaching tuberculosis levels. The virus is carried by an estimated 29 million Indians—the second-highest number globally. And yet, despite having a protective vaccine and effective antivirals for over three decades, we have failed to eliminate it. Why?advertisementThe painful truth: doctors have failed to engage society. We treated HBV as a medical issue, not a societal one like COVID-19, HIV or tuberculosis. For most people, the infection lasts less than six months. For others, it can get chronic and seriously damage the liver. Shockingly, less than 10 per cent of infected individuals are diagnosed; stigma around sexual transmission of the virus has led to under 5 per cent receiving treatment. This ignorance is far from bliss. The HBV can spread through blood, semen, saliva and other bodily fluids, as well as maternally. But the infected are not at the real case of 67-year-old Dr D. Basu (name changed) from Hubli. A CT scan for mild abdominal discomfort revealed a 5 cm liver cancer. He had tested HBV-positive 35 years ago, but never followed up or took treatment. He even hid the diagnosis from his family. When we treated his cancer, his brother and 37-year-old daughter Kalyani also tested positive, likely due to maternal transmission and later sexual or vertical transmission. This tragic case underlines some key precautions to follow. Periodic monitoring in the HBV-infected is a must—one in 10 of those infected develop cirrhosis or cancer. Patients undergo repeated testing but get no treatment as current guidelines are restrictive, excluding nearly 60 per cent from treatment. Patients live with anxiety, fear and stigma. We must move from treating a select few to treating all HBV-positives. One pill, like tenofovir, taken daily can suppress the virus lifelong, halt transmission and prevent Dr Basu's daughter, could have been protected with a birth dose. She was not given HBV vaccination at birth. India's birth-dose coverage is just 63 per cent. Despite being one of the cheapest vaccines and India being a major vaccine producer, the HBV vaccine is scarcely available in private markets here and public awareness is dismal. Only 4.4 per cent of Delhi's adults are fully vaccinated. Are you? Sadly, nearly one-third of health professionals aren't either. Every Indian child and adult should know: the HBV vaccine is safe, effective and for taught us the power of self-testing. All close contacts of the HBV-infected must be screened. Enact anti-discrimination laws in education, workplaces and healthcare. We need HBV kits to enable one-stop testing and treatment. At least 80 per cent of diagnosed patients must be linked to free, accessible treatment. Integrating HBV services with programmes for prenatal care, non-communicable diseases, HIV and tuberculosis is essential. We must integrate hepatitis testing into routine healthcare check-ups and general population-based screening. Pregnant women should be screened for both HBV and Hepatitis C Virus (HCV)—the latter spreads only through blood contact and affects 5.5 million launched the National Viral Hepatitis Control Program (NVHCP) on July 28, 2018—one of the world's largest campaigns aiming to eliminate viral hepatitis by 2030. It offers free diagnosis and treatment for HBV and HCV. While impressive work on screening has been done, the treatment uptake remains low. We need a massive awareness drive and a movement for public around 3,500 global hepatitis deaths daily—11 per cent from India—the crisis demands urgency. Every avoidable death is a call to act. Each preventable infection highlights our collective failure, and an opportunity to act. We need a society-wide approach, powered by political will, scientific leadership and strong community engagement. Let us break it down. No shame. No blame. Just a cure.—The author is Professor of Eminence, Chancellor, ILBS UniversitySubscribe to India Today Magazine- EndsTrending Reel


NDTV
5 hours ago
- NDTV
Liver Cancer May Kill 1.3 Million By 2050. Here's How to Stop It
A recent study published in The Lancet warns that liver cancer cases worldwide could nearly double by 2050 if current trends continue. New cases may rise from 870,000 to 1.52 million annually, with projected deaths reaching 1.37 million. Liver cancer is now the third deadliest cancer globally. The study highlights preventable causes such as alcohol use, viral hepatitis (B & C), and MASLD, a liver condition linked to obesity. Experts say that 60% of liver cancer cases could be avoided through early prevention and better public health strategies. The report was released on World Hepatitis Day and urges global action to reduce risk factors and improve awareness. Vaccination at birth is the best way to prevent hepatitis B, but vaccine coverage remains low in poorer countries including in sub-Saharan Africa, the study said. Unless vaccination rates are increased, hepatitis B is expected to kill 17 million people between 2015 and 2030, it added. Alcohol consumption is estimated to cause more than 21 percent of all cases of liver cancer by 2050, up more than two percentage points from 2022. Cancer due to obesity-linked fat in livers will rise to 11 percent, also up more than two percentage points, the researchers calculated. The large-scale study, which reviewed the available evidence on the subject, underscored "the urgent need for global action" on liver cancer, the authors said. The experts called for more public awareness about the preventable danger of liver cancer, particularly by warning people with obesity or diabetes about fatty-liver disease in the United States, Europe and Asia.


News18
6 hours ago
- News18
Reducing Risk Of Liver Cancer: A Call To Act On World Hepatitis Day
Last Updated: Let us understand the connection between hepatitis and liver cancer and what we can do to reduce the risk Every year, World Hepatitis Day, observed on July 28, brings global attention to one of the most pressing public health challenges — viral hepatitis, which affects over 350 million people worldwide. Among its many consequences, one of the gravest is liver cancer, particularly hepatocellular carcinoma (HCC), which often arises silently in the backdrop of chronic hepatitis B or C infections. On this important day, let us understand the connection between hepatitis and liver cancer and what we can do to reduce the risk. Understanding the link Chronic infection with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) is the leading cause of liver cancer globally. These viruses can silently inflame the liver for years, gradually leading to cirrhosis, genetic mutations, and ultimately cancer. According to WHO, up to 80% of liver cancer cases can be attributed to viral hepatitis. Simple blood tests (HBsAg for HBV, Anti-HCV for HCV) can identify carriers. Liver function tests and ultrasound help in early cancer detection. HBV: Long-term use of drugs like tenofovir or entecavir reduces viral replication and progression to cirrhosis or cancer. HCV: Direct-acting antivirals (DAAs) offer 95% cure rates, reducing the risk of liver cancer even in patients with advanced fibrosis. Avoid alcohol and toxins Chronic alcohol use and exposure to aflatoxins (from contaminated grains) synergize with hepatitis to worsen liver injury. Limiting or eliminating alcohol, ensuring food safety, and avoiding unnecessary herbal or over-the-counter medications that affect the liver are critical. Control of metabolic risk factors Conditions like diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD) are rising globally and may compound liver damage in viral hepatitis patients. Lifestyle changes — healthy diet, regular exercise, and glucose control — are essential. Regular surveillance in high-risk groups Individuals with chronic HBV or HCV, or with liver cirrhosis, should undergo regular ultrasound and alpha-fetoprotein (AFP) testing every 6 months. Early detection of HCC dramatically improves survival. A shared responsibility Preventing liver cancer is not just the responsibility of doctors or patients — it is a collective public health mission. Governments, communities, healthcare systems, and individuals must unite to: Improve awareness about viral hepatitis. Increase access to vaccination and testing. Eliminate the stigma around hepatitis. Expand availability of affordable treatment. Conclusion Liver cancer is largely preventable. On this World Hepatitis Day, let us commit to educate, vaccinate, test, and treat. With informed action today, we can ensure a future where hepatitis-related liver cancer becomes a rarity, not a global burden. Let's act now — for liver, lives, and for a hepatitis-free world. Dr Madhu Sasidharan is Senior Consultant, Department of Gastroenterology, KIMSHEALTH, Thiruvananthapuram. Views expressed in the above piece are personal and solely those of the author. They do not necessarily reflect News18's views. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.